Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Li Kang Biomedical CoROCO:6242 81 EBITDA Margin % is 21.65% as of Dec. 2025, which is 3% below its 10-year median of 22.33. GuruFocus rates ROCO:6242 with a GF Score™ of 81/100 and a GF Value™ of NT$38.95 (Fairly Valued). The stock has 3 warning signs investors should review. Among 840 Travel & Leisure companies, Li Kang Biomedical Co ranks better than 56.31% on this metric.
Li Kang Biomedical Co (ROCO:6242) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Li Kang Biomedical Co EBITDA Margin % Related Terms
Li Kang Biomedical Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Li Kang Biomedical Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6242 vs BKNG, ABNB, RCL: EBITDA Margin % Comparison
For the Travel Services subindustry, Li Kang Biomedical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Li Kang Biomedical Co EBITDA Margin % vs Travel & Leisure Industry
For the Travel & Leisure industry and Consumer Cyclical sector, Li Kang Biomedical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Li Kang Biomedical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Li Kang Biomedical Co (ROCO:6242) has a EBITDA Margin % of 21.65% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Li Kang Biomedical Co and its competitors. This is near median its historical median of 22.33. Over the past decade, Li Kang Biomedical Co's EBITDA Margin % has ranged from 18.75 to 31.58. According to the industry distribution chart, Li Kang Biomedical Co ranks #367 out of 840 companies in the Travel & Leisure industry, placing it in the top 43.7%.
Is Li Kang Biomedical Co's EBITDA Margin % too high?
Li Kang Biomedical Co's current EBITDA Margin % of 21.65% is near median its 10-year median of 22.33. Over the past 10 years, this metric has ranged from a low of 18.75 to a high of 31.58. The Travel & Leisure industry median EBITDA Margin % is 15.62. Li Kang Biomedical Co's value of 21.65% is 38.6% above this industry median. Based on the distribution chart, Li Kang Biomedical Co ranks #367 out of 840 companies in the Travel & Leisure industry, which is above the industry midpoint. Overall, Li Kang Biomedical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Li Kang Biomedical Co's EBITDA Margin % compare to BKNG and ABNB?
According to the Travel & Leisure industry distribution chart, Li Kang Biomedical Co ranks #367 out of 840 companies for EBITDA Margin %. This puts Li Kang Biomedical Co in the upper half of its industry. The industry median EBITDA Margin % is 15.62. Li Kang Biomedical Co's value of 21.65% is 38.6% above this benchmark. Historically, Li Kang Biomedical Co's own EBITDA Margin % has ranged from 18.75 to 31.58 over the past decade. While the company's 10-year median is 22.33 vs. the industry median of 15.62, Li Kang Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Travel & Leisure company?
The median EBITDA Margin % among Travel & Leisure companies is 15.62, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Li Kang Biomedical Co's current EBITDA Margin % of 21.65% is 38.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Li Kang Biomedical Co and its competitors. For the Travel & Leisure industry, the median EBITDA Margin % is 15.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Li Kang Biomedical Co's current EBITDA Margin % is 21.65%, which is near median its own 10-year median of 22.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Li Kang Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Li Kang Biomedical Co (ROCO:6242) is currently considered Fairly Valued. The stock's GF Value™ is NT$38.95, compared to a current price of NT$35.95 — trading 7.7% below its estimated fair value. The current EBITDA Margin % is 21.65%, which is near median its 10-year median of 22.33 and 38.6% above the Travel & Leisure industry median of 15.62. Li Kang Biomedical Co's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Li Kang Biomedical Co (ROCO:6242), the current EBITDA Margin % is 21.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Li Kang Biomedical Co (ROCO:6242) Overvalued in 2026?
Based on GuruFocus' analysis, Li Kang Biomedical Co stock appears to be undervalued.
The current stock price of NT$35.95 is trading 7.7% below its estimated GF Value™ of NT$38.95.
GuruFocus considers Li Kang Biomedical Co to be Fairly Valued.
Key valuation signals for ROCO:6242:
EBITDA Margin %: 21.65% (near median its 10-year median of 22.33)
GF Value™: NT$38.95 vs. price of NT$35.95 (7.7% below fair value)
Industry Position: 38.6% above the Travel & Leisure median (#367 of 840)
No single metric tells the full story. See the ROCO:6242 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Li Kang Biomedical Co Ltd is a Taiwan based company engages in tourism factory businesses, telemarketing, as well as the manufacturing and sales of cosmetics and hygienic drinks.
81GF Score
Get the complete analysis for ROCO:6242
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6242 has been successfully added to your 
